aTyr Pharma, Inc. (ATYR) Income Statement
ATYR 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsATYR revenue and net income
Where ATYR's revenue goes
2025Each bar shows an amount and its share of revenue. ATYR kept −39,009.5% of revenue as net income.
ATYR profit margins
ATYR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −19.1% | −73.7% | −55.1% | — |
| Gross profit | −680.0% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ATYR quarterly EPS vs estimates
aTyr Pharma beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.11).
ATYR income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190,000 | $235,000 | $353,000 | $10.4M | $0 | $10.5M | $422,000 | $0 | $0 | $0 |
| Cost of revenue | $1.6M | $1.5M | $2.7M | $1.7M | $1.3M | $17.3M | $14.0M | $746,000 | $713,000 | $900,000 |
| Gross profit | −$1.4M | $235,000 | $353,000 | $8.7M | −$1.3M | −$6.8M | −$13.6M | −$746,000 | −$713,000 | −$900,000 |
| Research & development | $60.2M | $54.4M | $42.3M | $42.8M | $23.3M | $17.3M | $14.0M | $20.4M | $30.1M | $44.2M |
| Sales, general & admin | $17.6M | $13.8M | $13.0M | $14.0M | $10.8M | $9.1M | $9.4M | — | — | — |
| Total operating expenses | $76.3M | $68.1M | $55.3M | $55.1M | $32.7M | $9.1M | $9.4M | $32.1M | $46.4M | $58.4M |
| Operating income | −$77.6M | −$67.9M | −$54.9M | −$46.4M | −$34.0M | −$15.9M | −$23.0M | −$32.8M | −$47.1M | −$59.3M |
| Income before taxes | −$74.1M | −$64.0M | −$50.4M | −$45.3M | −$33.8M | −$16.2M | −$23.8M | −$34.5M | −$48.2M | −$57.9M |
| Income taxes | — | — | −$8,000 | −$5,000 | −$9,000 | −$6,000 | −$160,000 | $1 | — | −$49,000 |
| Net income | −$74.1M | −$64.0M | −$50.4M | −$45.3M | −$33.8M | −$16.2M | −$23.6M | −$34.5M | −$48.2M | −$57.9M |
| EBITDA | −$72.6M | −$62.5M | −$47.7M | −$43.6M | −$32.5M | −$14.6M | −$22.3M | −$32.1M | −$46.4M | −$57.0M |
| EPS (diluted) | −$0.79 | −$0.87 | −$0.96 | −$1.60 | −$1.88 | −$1.59 | −$7.33 | −$16.24 | −$26.46 | −$56.68 |
| Gross margin | −717.4% | 100.0% | 100.0% | 83.7% | — | −65.4% | −3,228.9% | — | — | — |
| Operating margin | −40,856.3% | −28,899.6% | −15,557.8% | −446.8% | — | −152.2% | −5,445.0% | — | — | — |
| Net margin | −39,009.5% | −27,243.8% | −14,274.5% | −436.5% | — | −155.2% | −5,593.1% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $190,000 | $0 | $0 | $0 | $0 | $0 | $235,000 | $0 | $353,000 |
| Cost of revenue | $405,000 | $394,000 | $394,000 | $22.1M | $387,000 | $383,000 | $12.2M | $388,000 | $383,000 | $770,000 | $407,000 | $993,000 |
| Gross profit | −$405,000 | −$394,000 | −$394,000 | −$21.9M | −$387,000 | −$383,000 | −$12.2M | −$388,000 | −$383,000 | $235,000 | −$407,000 | −$640,000 |
| Research & development | $6.7M | $7.3M | $10.9M | $22.1M | $15.4M | $11.8M | $12.2M | $14.8M | $14.0M | $13.4M | $12.8M | $10.3M |
| Sales, general & admin | $4.1M | $4.1M | $3.9M | $4.8M | $4.9M | $4.0M | $3.6M | $3.3M | $3.3M | $3.5M | $3.2M | $2.6M |
| Total operating expenses | $10.5M | $11.0M | $14.8M | $4.8M | $20.3M | $15.8M | $3.6M | $18.1M | $17.3M | $16.9M | $15.6M | $12.0M |
| Operating income | −$10.9M | −$11.4M | −$14.8M | −$26.7M | −$20.3M | −$15.8M | −$15.8M | −$18.1M | −$17.3M | −$16.6M | −$16.0M | −$12.6M |
| Income before taxes | −$10.3M | −$10.8M | −$14.0M | −$25.7M | −$19.5M | −$14.9M | −$15.0M | −$17.3M | −$16.3M | −$15.5M | −$14.8M | −$11.3M |
| Income taxes | — | — | — | — | — | — | — | — | −$1 | $4,000 | −$1,000 | −$2,000 |
| Net income | −$10.3M | −$10.8M | −$14.0M | −$25.7M | −$19.5M | −$14.9M | −$15.0M | −$17.3M | −$16.3M | −$15.5M | −$14.8M | −$11.3M |
| EBITDA | −$10.5M | −$10.4M | −$13.6M | −$25.4M | −$19.1M | −$14.5M | −$14.8M | −$16.9M | −$15.9M | −$14.7M | −$14.4M | −$10.3M |
| EPS (diluted) | −$0.11 | −$0.11 | −$0.14 | −$0.26 | −$0.22 | −$0.17 | −$0.18 | −$0.23 | −$0.23 | −$0.23 | −$0.25 | −$0.20 |
| Gross margin | — | — | — | −11,547.4% | — | — | — | — | — | 100.0% | — | −181.3% |
| Operating margin | — | — | — | −14,076.3% | — | — | — | — | — | −7,079.1% | — | −3,573.7% |
| Net margin | — | — | — | −13,549.5% | — | — | — | — | — | −6,591.9% | — | −3,212.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ATYR's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ATYR financial results
In fiscal year 2025 (ended December 31, 2025), aTyr Pharma reported revenue of $0.2 million, down 19.1% from the year before. It had a net loss of $74.1 million, a net profit margin of −39,009.5%. Diluted earnings per share came to −$0.79. Over five years revenue grew at an average rate of −55.1% a year.
See the ATYR stock overview for the latest quote and news, or the ATYR chart for price history and technical indicators.
ATYR income statement FAQ
What is aTyr Pharma's annual revenue?
aTyr Pharma reported total revenue of $0.2 million for fiscal year 2025, which ended on December 31, 2025. That was down 19.1% from $0.2 million the previous year.
Is aTyr Pharma profitable?
No. aTyr Pharma reported a net loss of $74.1 million in fiscal 2025, a net profit margin of −39,009.5%; its operating margin was −40,856.3%.
What is aTyr Pharma's gross margin?
aTyr Pharma's gross margin was −717.4% in fiscal 2025: for every $100 of revenue, aTyr Pharma kept $-717 after the direct cost of its products and services.
How much does aTyr Pharma spend on research and development?
aTyr Pharma spent $60.2 million on research and development in fiscal 2025, 31,694.2% of revenue.
How fast is aTyr Pharma growing?
Revenue grew −55.1% a year on average over the last five fiscal years, from $10.5 million to $0.2 million.
What are aTyr Pharma's earnings per share?
aTyr Pharma earned $-0.79 per diluted share in fiscal 2025, compared with $-0.87 a year earlier.
When will aTyr Pharma report its next earnings?
aTyr Pharma is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does aTyr Pharma's fiscal year end?
aTyr Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.